Dat	e:May.29 <sup>th</sup> , 2	2022	
Υοι	ır Name:Yi	ilin Pi	
Ма	nuscript Title:	NPRL2 as a Potentia	Il Biomarker for the Prognosis and Immunotherapy of Stomach
Ma	nuscript number (if known)	):JGO-22	2-115
rela par to t rela	ated to the content of your ties whose interests may be transparency and does not ationship/activity/interest,	manuscript. "Related" e affected by the conte necessarily indicate a b it is preferable that yo	
	nuscript only.	to the author's relatio	nships/activities/interests as they relate to the <u>current</u>
to t me In i	he epidemiology of hypertodication, even if that medic	ension, you should dec cation is not mentioned pport for the work rep	d be <u>defined broadly</u> . For example, if your manuscript pertains clare all relationships with manufacturers of antihypertensive d in the manuscript.  Forted in this manuscript without time limit. For all other items,
		Name all entities with	Supplies the second sec
		whom you have this	Specifications/Comments (e.g., if payments were made to you or to your
		relationship or indicate	
		none (add rows as	,
		needed)	
		Time frame: Since the i	nitial planning of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Timo framou	past 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	past 30 months
3	Royalties or licenses	XNone	
l l	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
U	testimony		
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	V. None	
10	in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
13	services Other financial or non-	X None	
13	financial interests		
	manetal interests		
Ple	ease summarize the above c	onflict of interest in the f	ollowing box:
	None		
L			

Dat	e:May.29 <sup>th</sup> , 2	2022	
You	ır Name:Y	uning Zhan	
Ma	uscript Title:NPRL2 as a Potential Biomarker for the Prognosis and Immunotherapy of Stomach		
Ade	enocarcinoma		
Ma	nuscript number (if known)	):JGO-22-11 <u>!</u>	 5
rela par to t rela	ited to the content of your ties whose interests may b ransparency and does not ationship/activity/interest,	manuscript. "Related" me e affected by the content on necessarily indicate a bias. it is preferable that you do	I relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a poso.
	nuscript only.	to the dutilor 5 relations.	ps, detivities, interests as they relate to the <u>earrent</u>
to t med	he epidemiology of hypert dication, even if that medic	ension, you should declare cation is not mentioned in t pport for the work reporte	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.  ed in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initia	l planning of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
	Canadalina for	V. Name	
+ I	Consulting fees	X None	l l

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
_			
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
		., .,	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
12	services	V None	
13	Other financial or non- financial interests	XNone	
	imanciai interests		
PIE	ease summarize the above c	onflict of interest in the	following box:
	None		

Date	e:May.29 <sup>th</sup> , 2	2022	
Mar	nuscript Title:NPRL2 as a Potential Biomarker for the Prognosis and Immunotherapy of Stomach		
Ade	nocarcinoma		 5
Mar	nuscript number (if known)	:JGO-22-11	5
rela part to ti rela	ted to the content of your ties whose interests may be ransparency and does not tionship/activity/interest,	manuscript. "Related" me e affected by the content on necessarily indicate a bias. it is preferable that you do	I relationships/activities/interests listed below that are cans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment. If you are in doubt about whether to list a o so.  ips/activities/interests as they relate to the current
	nuscript only.		<u></u>
to tl med In it	he epidemiology of hyperto dication, even if that medic	ension, you should declare ation is not mentioned in pport for the work reporte	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.  ed in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initia	l planning of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	t 36 months
	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
ı	Consulting fees	X None	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
_			
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
		., .,	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
12	services	V None	
13	Other financial or non- financial interests	XNone	
	imanciai interests		
PIE	ease summarize the above c	onflict of interest in the	following box:
	None		

Date	e:May.29 <sup>th</sup> , 2	2022	
You	r Name:X	in Jin	
Man	nuscript Title:	NPRL2 as a Potential Bi	omarker for the Prognosis and Immunotherapy of Stomach
Ade	nocarcinoma		
Man	nuscript number (if known)	):JGO-22-11	 .5
relat part to tr relat	ted to the content of your ies whose interests may be ransparency and does not tionship/activity/interest,	manuscript. "Related" me e affected by the content necessarily indicate a bias it is preferable that you d	Il relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment is. If you are in doubt about whether to list a o so.
	uscript only.		
to the med	ne epidemiology of hyperto lication, even if that medic	ension, you should declare cation is not mentioned in pport for the work reporte	e <u>defined broadly</u> . For example, if your manuscript pertains e all relationships with manufacturers of antihypertensive the manuscript.  ed in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initia	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: pas	t 36 months
i	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3 1	Royalties or licenses	XNone	
1 (	Consulting fees	X None	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
_			
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
		., .,	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
12	services	V None	
13	Other financial or non- financial interests	XNone	
	imanciai interests		
PIE	ease summarize the above c	onflict of interest in the	following box:
	None		

Dat	e:May.29 <sup>th</sup> , 2	2022	
Ma	nuscript Title:	NPRL2 as a Potential Bio	omarker for the Prognosis and Immunotherapy of Stomach
Add	enocarcinoma		 5
Ma	nuscript number (if known)	:JGO-22-11	5
In t rela par to t rela The ma The to t me	he interest of transparency ated to the content of your ties whose interests may be transparency and does not not interest ationship/activity/interest, ationship/activity/interest, ationship questions apply nuscript only.	we ask you to disclose al manuscript. "Related" me affected by the content on ecessarily indicate a biastit is preferable that you do to the author's relationsh ivities/interests should be ension, you should declare ation is not mentioned in apport for the work reported.	I relationships/activities/interests listed below that are cans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment. If you are in doubt about whether to list a poso.  ips/activities/interests as they relate to the current  defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	l planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	X_None	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
_			
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
		., .,	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
12	services	V None	
13	Other financial or non- financial interests	XNone	
	imanciai interests		
PIE	ease summarize the above c	onflict of interest in the	following box:
	None		